• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

Opinion
Video

Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.

Video content above is prompted by the following:

  • Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
4 KOLs are featured in this series
4 KOLs are featured in this series
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.